Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines.

[1]  S. Chanock,et al.  Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies , 2018, Vaccine.

[2]  M. Pawlita,et al.  Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. , 2018, Vaccine.

[3]  D. Lowy,et al.  Explanations for the high potency of HPV prophylactic vaccines , 2018, Vaccine.

[4]  J. Dillner,et al.  Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development , 2018, Vaccine.

[5]  M. Gail,et al.  Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine. , 2018, Contemporary clinical trials.

[6]  M. Gail,et al.  Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial , 2018, Journal of the National Cancer Institute.

[7]  D. Harper,et al.  HPV vaccines - A review of the first decade. , 2017, Gynecologic oncology.

[8]  D. Lowy,et al.  Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. , 2015, The Lancet. Oncology.

[9]  D. Lowy,et al.  Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. , 2015, The Lancet. Oncology.

[10]  M. Einstein,et al.  Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial , 2014, Human vaccines & immunotherapeutics.

[11]  M. Pawlita,et al.  Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18. , 2014, Vaccine.

[12]  S. Wacholder,et al.  Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. , 2014, Vaccine.

[13]  D. Lowy,et al.  Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three Assays , 2014, Front. Oncol..

[14]  D. Lowy,et al.  Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial , 2013, Cancer Prevention Research.

[15]  J. Singer,et al.  Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. , 2013, JAMA.

[16]  L. Bruni,et al.  Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report. , 2012, Vaccine.

[17]  M. Jit,et al.  Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[18]  Who,et al.  Human papillomavirus vaccines: WHO position paper. , 2009, Biologicals : journal of the International Association of Biological Standardization.